ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 572-580

  Smith, A M ^a   Findlay, V J ^a   Bandurraga, S G ^a   Kistner Griffin, E ^a   Spruill, L S ^a   Liu, A ^b   Golshayan, A R ^b   Turner, D P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84863282423     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs007     Document Type: Article

References (54)

1. Jemal,A. et al. (2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
2. Schroder,F.H. et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med., 360, 1320-1328.
3. Bangma,C.H. et al. (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J. Urol., 25, 3-9.
4. Heidenreich,A. et al. (2009) [EAU guidelines on prostate cancer]. Actas Urol. Esp., 33, 113-126.
5. Heidenreich,A. et al. (2008) EAU guidelines on prostate cancer. Eur. Urol., 53, 68-80.
6. Loblaw,D.A. et al. (2007) Initial hormonal management of androgensensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol., 25, 1596-1605.
7. Chang,S.S. (2007) Treatment options for hormone-refractory prostate cancer. Rev. Urol., 9 (suppl. 2), S13-S18.
8. Kish,J.A. et al. (2001) The treatment challenge of hormone-refractory prostate cancer. Cancer Control, 8, 487-495.
9. Wang,Q. et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138, 245-256.
10. Chen,C.D. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med., 10, 33-39.
11. Turner,D.P. (2010) The role of ETS transcriptional regulation in hormone sensitive and refractory prostate cancer. Open Cancer J., 3, 40-48.
12. Massie,C.E. et al. (2007) New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep., 8, 871-878.
13. Schneikert,J. et al. (1996) Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J. Biol. Chem., 271, 23907-23913.
14. Singh,S. et al. (2002) ETS proteins and MMPs: partners in invasion and metastasis. Curr. Drug Targets, 3, 359-367.
15. Preece,D.M. et al. (2011) ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells. Prostate, 71, 403-414.
16. Asadi,F. et al. (2005) Parathyroid hormone-related protein in prostate cancer. Crit. Rev. Eukaryot. Gene Expr., 15, 15-28.
17. Chen,H. et al. (2002) NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res., 62, 338-340.
18. Tomlins,S.A. et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat. Genet., 39, 41-51.
19. Tomlins,S.A. et al. (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol., 56, 275-286.
20. Attard,G. et al. (2009) Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J. Clin. Pathol., 62, 373-376.
21. Rickman,D.S. et al. (2010) ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. Neoplasia, 12, 1031-1040.
22. Seth,A. et al. (2005) ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer, 41, 2462-2478.
23. Turner,D.P. et al. (2008) ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev. Anticancer Ther., 8, 33-42.
24. Alipov,G. et al. (2005) Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas. Histopathology, 46, 202-208.
25. Span,P.N. et al. (2002) Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene, 21, 8506-8509.
26. Davidson,B. et al. (2001) Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin. Cancer Res., 7, 551-557.
27. Pande,P. et al. (2001) Prognostic impact of Ets-1 overexpression in betel and tobacco related oral cancer. Cancer Detect. Prev., 25, 496-501.
28. Dittmer,J. (2003) The biology of the Ets1 proto-oncogene. Mol. Cancer, 2, 29.
29. Verschoor,M.L. et al. (2010) Ets-1 regulates energy metabolism in cancer cells. PLoS One, 5, e13565.
30. Kosaka,T. et al. (2007) Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate, 67, 41-49.
31. Kosaka,T. et al. (2011) Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer. Prostate., 71, 1510-1517.
32. Kosaka,T. et al. (2010) Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate, 70, 162-169.
33. Thalmann,G.N. et al. (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate, 44, 91-103. Jul 1; 44 (2).
34. Thalmann,G.N. et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54, 2577-2581.
35. Wang,S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
36. Sobel,R.E. et al. (2005) Cell lines used in prostate cancer research: a compendium of old and new lines-part 1. J. Urol., 173, 342-359.
37. Pufall,M.A. et al. (2005) Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science, 309, 142-145.
38. Callaway,K. et al. (2010) Phosphorylation of the transcription factor Ets-1 by ERK2: rapid dissociation of ADP and phospho-Ets-1. Biochemistry, 49, 3619-3630.
39. Tootle,T.L. et al. (2005) Post-translational modifications influence transcription factor activity: a view from the ETS superfamily. Bioessays, 27, 285-298.
40. Foulds,C.E. et al. (2004) Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol. Cell Biol., 24, 10954-10964.
41. Nelson,M.L. et al. (2010) Ras signaling requires dynamic properties of Ets1 for phosphorylation-enhanced binding to coactivator CBP. Proc. Natl Acad. Sci. USA, 107, 10026-10031.
42. Shen,M.M. et al. (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev., 24, 1967-2000.
43. Ghosh,P.M. et al. (2005) Signal transduction pathways in androgendependent and -independent prostate cancer cell proliferation. Endocr. Relat. Cancer, 12, 119-134.
44. Ghosh,P.M. et al. (2003) Akt in prostate cancer: possible role in androgenindependence. Curr. Drug Metab., 4, 487-496.
45. Munro,N.P. et al. (2010) Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years. Radiother. Oncol., 96, 34-37.
46. Goetz,T.L. et al. (2000) Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2. Mol. Cell. Biol., 20, 81-90.
47. Abreu-Martin,M.T. et al. (1999) Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell. Biol., 19, 5143-5154.
48. Bakin,R.E. et al. (2003) Constitutive activation of the Ras/mitogenactivated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res., 63, 1981-1989.
49. Franco,O.E. et al. (2003) Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate, 56, 319-325.
50. Mukherjee,R. et al. (2011) Upregulation ofMAPK pathway is associated with survival in castrate-resistant prostate cancer. Br. J. Cancer, 104, 1920-1928.
51. Gioeli,D. et al. (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res., 59, 279-284.
52. Weinstein-Oppenheimer,C.R. et al. (2000) The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factorresponsive tumors. Pharmacol. Ther., 88, 229-279.
53. Kinkade,C.W. et al. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest., 118, 3051-3064.
54. Kreisberg,J.I. et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res., 64, 5232-5236.